2024
Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA
Inzucchi S, Tan X, Liang Y, Yedigarova L, Xie L, de Havenon A. Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA. Diabetes Therapy 2024, 1-17. PMID: 39688779, DOI: 10.1007/s13300-024-01678-4.Peer-Reviewed Original ResearchHealth care resource utilizationAtherosclerotic cardiovascular diseaseDPP-4i usersDPP-4isGLP-1 RAsOnce-weekly semaglutideMedical costsType 2 diabetesDPP-4iDecreased risk of strokeRisk of cardiovascular outcomesCardiovascular eventsOnce-weekly GLP-1 RAsPeptide 1 receptor agonistsTotal medical costsDipeptidyl peptidase 4 inhibitorsOccurrence of cardiovascular eventsHigh-risk patientsRisk of strokeObservational cohort analysisData Mart DatabaseOutpatient visitsDecreased riskSemaglutide treatmentBaseline characteristics
2023
791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD
TAN X, LIANG Y, RAJPURA J, YEDIGAROVA L, NOONE J, XIE L, DE HAVENON A. 791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD. Diabetes 2023, 72 DOI: 10.2337/db23-791-p.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseGLP-1 RAsMyocardial infarctionDPP-4iIschemic strokeCardiovascular eventsNovo NordiskGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistMajor adverse cardiovascular eventsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsRisk of MINew adult usersAdverse cardiovascular eventsRetrospective cohort studyPeptidase-4 inhibitorsDPP-4 inhibitorsType 2 diabetesReal-world evidenceDrug discontinuationBaseline characteristicsCohort studyOptum ClinformaticsReceptor agonistChange in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial
Anadani M, Turan T, Yaghi S, Spiotta A, Gory B, Sharma R, Sheth K, de Havenon A. Change in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial. Stroke 2023, 54: 921-927. PMID: 36876480, PMCID: PMC10050138, DOI: 10.1161/strokeaha.121.038202.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsAcute ischemic strokeIschemic strokeCardiovascular eventsPersistent smokersPersistent smokingSPS3 trialSmoking statusMyocardial infarctionMajor adverse cardiovascular events outcomesCardiovascular event outcomesMajor cardiovascular outcomesSubsequent cardiovascular eventsHistory of hypertensionRisk of strokeEnd of studyPost Hoc AnalysisPrior smokersRandomization armCardiovascular outcomesFormer smokersMonth 3Primary outcomeTotal cohort
2022
Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity
Schneider D, Honda T, Feldmann E, de Havenon A, Romano J, Nogueira R, Prabhakaran S, Mishra N, Beaman C, Hinman J, Commichau C, Callas P, Kaneko N, Morales J, Patel S, Sharma L, Kim S, Taatjes‐Sommer H, Liebeskind D. Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity. Stroke Vascular And Interventional Neurology 2022, 2 DOI: 10.1161/svin.121.000201.Peer-Reviewed Original ResearchStroke/transient ischemic attackTransient ischemic attackRecent myocardial infarctionMyocardial infarctionPlatelet expressionFcγRIIa expressionNeurologic dysfunctionPlatelet reactivitySubsequent stroke/transient ischemic attacksSubsequent cardiovascular eventsEmbolic causesNonembolic causesPlatelet FcγRIIACardiovascular eventsIschemic attackIdentifies patientsIschemic strokeMethods PatientsDischarge diagnosisTreatment decisionsLower riskPatientsPlatelet activationFlow cytometryEmbolic
2021
Midlife Blood Pressure Variability and Risk of All-Cause Mortality and Cardiovascular Events During Extended Follow-up
de Havenon A, Delic A, Yaghi S, Wong KH, Majersik JJ, Stulberg E, Tirschwell D, Anadani M. Midlife Blood Pressure Variability and Risk of All-Cause Mortality and Cardiovascular Events During Extended Follow-up. American Journal Of Hypertension 2021, 34: 1269-1275. PMID: 34240111, PMCID: PMC8643578, DOI: 10.1093/ajh/hpab106.Peer-Reviewed Original ResearchConceptsBlood pressure variabilityLong-term blood pressure variabilityCardiovascular eventsHazard ratioPressure variabilityCardiovascular disease-free participantsMean systolic blood pressureVisit blood pressure variabilityCox proportional hazards modelCardiovascular risk factorsCorresponding hazard ratiosCongestive heart failureDisease-free patientsSystolic blood pressureDisease-free participantsProportional hazards modelPrior strokeCause mortalitySecondary outcomesBlood pressureHeart failureIndependent predictorsPrimary outcomeVisit 4Mean ageWhite Matter Hyperintensity and Cardiovascular Disease Outcomes in the SPRINT MIND Trial
Sheibani N, Wong KH, Turan TN, Yeatts SD, Gottesman RF, Prabhakaran S, Rost NS, de Havenon A. White Matter Hyperintensity and Cardiovascular Disease Outcomes in the SPRINT MIND Trial. Journal Of Stroke And Cerebrovascular Diseases 2021, 30: 105764. PMID: 33823461, PMCID: PMC8107132, DOI: 10.1016/j.jstrokecerebrovasdis.2021.105764.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialWhite matter hyperintensity volumeSystolic blood pressurePrimary outcomeHazard ratioLog-transformed white matter hyperintensity volumeGoal systolic blood pressureLog-transformed continuous variableComposite of strokeIntensive BP loweringHigh cardiovascular riskAcute coronary syndromeCongestive heart failureProspective clinical trialsCardiovascular disease outcomesFuture CVD riskWhite matter hyperintensitiesSubset of participantsBP loweringCardiovascular deathCardiovascular eventsCoronary syndromeCardiovascular riskCVD riskBlood pressure
2019
Blood Pressure Variability and Cardiovascular Outcomes in Patients With Prior Stroke
de Havenon A, Fino NF, Johnson B, Wong KH, Majersik JJ, Tirschwell D, Rost N. Blood Pressure Variability and Cardiovascular Outcomes in Patients With Prior Stroke. Stroke 2019, 50: 3170-3176. PMID: 31537194, PMCID: PMC6817411, DOI: 10.1161/strokeaha.119.026293.Peer-Reviewed Original ResearchConceptsBlood pressure variabilityMajor cardiovascular eventsDiastolic blood pressure variabilityRecurrent ischemic strokeRecurrent strokeModifiable risk factorsCause deathCardiovascular eventsIschemic strokePrior strokeRisk factorsPressure variabilitySystolic blood pressure variabilitySecondary stroke preventionSystolic blood pressureAntihypertensive medicationsPRoFESS trialCardiovascular outcomesStroke preventionHazard ratioBlood pressureHigh morbidityLarge trialsCardiovascular diseasePrimary stroke